Cargando…

Efficacy of Rituximab in Treatment-Resistant Focal Segmental Glomerulosclerosis With Elevated Soluble Urokinase-Type Plasminogen Activator Receptor and Activation of Podocyte β3 Integrin

INTRODUCTION: Severe, nonresponsive, primary focal segmental glomerular sclerosis (FSGS) can progress to end-stage kidney disease (ESKD) in <5 years. Soluble urokinase-type plasminogen activator receptor (suPAR) may contribute to podocyte effacement by activating podocyte β3 integrin. It has been...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hladunewich, Michelle A., Cattran, Dan, Sethi, Sanjeev M., Hayek, Salim S., Li, Jing, Wei, Changli, Mullin, Sarah I., Reich, Heather N., Reiser, Jochen, Fervenza, Fernando C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720804/ https://www.ncbi.nlm.nih.gov/pubmed/35005315 http://dx.doi.org/10.1016/j.ekir.2021.10.017

Ejemplares similares

Focal Segmental Glomerulosclerosis: Assessing the Risk of Relapse
por: Troyanov, Stéphan, et al.
Publicado: (2023)

In silico docking of urokinase plasminogen activator and integrins
por: Degryse, Bernard, et al.
Publicado: (2008)

Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis
por: Lee, Ji-Hye, et al.
Publicado: (2014)

Quantifying the benefits of remission duration in focal and segmental glomerulosclerosis
por: Jauhal, Arenn, et al.
Publicado: (2022)

Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models
por: Chen, Jin-Shuen, et al.
Publicado: (2016)

Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin's Lymphoma
por: Kouhpayeh, Shirin, et al.
Publicado: (2017)

Erratum to: Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models
por: Chen, Jin-Shuen, et al.
Publicado: (2017)

Serum soluble urokinase type plasminogen activated receptor and focal segmental glomerulosclerosis: a systematic review and meta-analysis
por: Shuai, Tiankui, et al.
Publicado: (2019)

Focal and segmental glomerulosclerosis: clinical and kidney biopsy correlations
por: Sethi, Sanjeev, et al.
Publicado: (2014)

Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes
por: Alfano, Massimo, et al.
Publicado: (2015)

Secondary Focal Segmental Glomerulosclerosis: From Podocyte Injury to Glomerulosclerosis
por: Kim, Jae Seok, et al.
Publicado: (2016)

Clinical and pathological phenotype of genetic causes of focal segmental glomerulosclerosis in adults
por: Lepori, Nicola, et al.
Publicado: (2018)

Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method
por: Winnicki, Wolfgang, et al.
Publicado: (2019)

Fetal Renal Echogenicity Associated with Maternal Focal Segmental Glomerulosclerosis: The Effect of Transplacental Transmission of Permeability Factor suPAR
por: Shuster, Shirley, et al.
Publicado: (2018)

Prospective Cohort Study of Soluble Urokinase Plasminogen Activation Receptor and Cardiovascular Events in Patients With CKD
por: Sommerer, Claudia, et al.
Publicado: (2023)

Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab
por: Alachkar, Nada, et al.
Publicado: (2018)

Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia
por: Rovina, Nikoletta, et al.
Publicado: (2020)

A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy
por: Hladunewich, Michelle A., et al.
Publicado: (2014)

Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19
por: Luo, Shengyuan, et al.
Publicado: (2022)

In IgA Nephropathy, Glomerulosclerosis Is Associated with Increased Urinary CD80 Excretion and Urokinase-Type Plasminogen Activator Receptor-Positive Podocyturia
por: Trimarchi, Hernán, et al.
Publicado: (2017)

Localization of Urokinase‐type Plasminogen Activator, Plasminogen Activator Inhibitor‐1, 2 and Plasminogen in Colon Cancer
por: Naitoh, Hiroyuki, et al.
Publicado: (1995)

Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis
por: Hindy, George, et al.
Publicado: (2022)

A multicolor podocyte reporter highlights heterogeneous podocyte changes in focal segmental glomerulosclerosis
por: Tao, Jianling, et al.
Publicado: (2013)

Role of Podocyte Injury in Glomerulosclerosis
por: Lu, Chen-Chen, et al.
Publicado: (2019)

A Case of Podocytic Infolding Glomerulopathy with Focal Segmental Glomerulosclerosis
por: Iguchi, Akira, et al.
Publicado: (2013)

Podocyte and endothelial injury in focal segmental glomerulosclerosis: an ultrastructural analysis
por: Taneda, Sekiko, et al.
Publicado: (2015)

Exogenous Urokinase Inhibits Proteasomal Degradation of Its Cognate Urokinase Plasminogen Activator Receptor
por: Zhu, Ran, et al.
Publicado: (2022)

Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors
Publicado: (1987)

Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse
Publicado: (1984)

Ultrastructural localization of plasma membrane-associated urokinase- type plasminogen activator at focal contacts
Publicado: (1988)

Rituximab treatment of adults with primary focal segmental glomerulosclerosis
por: Wang, Liuwei, et al.
Publicado: (2023)

Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography
por: Sommerer, Claudia, et al.
Publicado: (2019)

Identification of glomerular and podocyte-specific genes and pathways activated by sera of patients with focal segmental glomerulosclerosis
por: Otalora, Lilian, et al.
Publicado: (2019)

Sex Differences in Circulating Soluble Urokinase‐Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease
por: Mehta, Anurag, et al.
Publicado: (2020)

Unwinding focal segmental glomerulosclerosis
por: Peev, Vasil, et al.
Publicado: (2017)

Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High‐Sensitivity C‐Reactive Protein
por: Hayek, Salim S., et al.
Publicado: (2018)

Proteomics of Plasma and Plasma-Treated Podocytes: Application to Focal and Segmental Glomerulosclerosis
por: Chhuon, Cerina, et al.
Publicado: (2023)

Therapeutic Potential Targeting Podocyte Mitochondrial Dysfunction in Focal Segmental Glomerulosclerosis
por: Li, Yuting, et al.
Publicado: (2023)

Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.
por: Knoop, A., et al.
Publicado: (1998)

Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation
por: Gupta, Kamlesh K., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5gb88jdrute9qgret4f31l2hfj